Investigating the structure and regulation of a liver receptor important for metabolism
Full-length LRH-1 structural regulation
This study is looking at a key protein in the liver that helps control cholesterol and sugar levels, with the goal of finding new ways to create medicines that could help people with type 2 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-10697397 on NIH RePORTER |
What this research studies
This research focuses on LRH-1, a nuclear receptor that plays a crucial role in liver functions such as cholesterol and glucose regulation. By using advanced structural biology techniques, the team aims to understand how different parts of LRH-1 communicate and work together, which could lead to the development of new drugs targeting this receptor. The study involves creating detailed models of LRH-1 to facilitate drug design efforts, potentially leading to effective treatments for conditions like type 2 diabetes. Patients may benefit from insights gained in this research as it could pave the way for new therapeutic options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with type 2 diabetes or related metabolic disorders.
Not a fit: Patients who do not have metabolic disorders or type 2 diabetes may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new medications that improve liver metabolism and manage type 2 diabetes more effectively.
How similar studies have performed: While there has been progress in targeting nuclear receptors for drug development, the specific approach of understanding LRH-1's full-length structure is relatively novel and has not been extensively tested.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Blind, Raymond Daniel — Vanderbilt University Medical Center
- Study coordinator: Blind, Raymond Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.